UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000034113 |
|---|---|
| Receipt number | R000037921 |
| Scientific Title | Prophylaxis of HBV reactivation by vaccination enforcing post-transplant HBV immunity |
| Date of disclosure of the study information | 2018/09/24 |
| Last modified on | 2022/09/16 10:43:33 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Prophylaxis of HBV reactivation by vaccination enforcing post-transplant HBV immunity
Acronym
PREVENT HBV
Scientific Title
Prophylaxis of HBV reactivation by vaccination enforcing post-transplant HBV immunity
Scientific Title:Acronym
PREVENT HBV
Region
| Japan |
Condition
Condition
HSCT recipient with resolved infection of HBV
Classification by specialty
| Hematology and clinical oncology | Infectious disease |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
Prospective Randomized trial to show efficacy of post-HSCT HB vaccination against HBV reactivation
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
HBV reactivation
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Open -no one is blinded
Control
No treatment
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Prevention
Type of intervention
| Vaccine |
Interventions/Control_1
HB vaccine arm
HBV DNA and anti-HBs antibody are monitored every 28 days, and preemptive nucleoside analogue is administered when reactivation of HBV is observed.
Inoculations of HB vaccine are planed on day 196, day 224, and day 364 after HSCT.
If the titer of anti-HBs antibody is less than 10 mIU/mL on day392, additional vaccines are planed on day 420, day 448, and day 588 after HSCT.
Interventions/Control_2
non-HB vaccine arm
HBV DNA and anti-HBs antibody are monitored every 28 days, and preemptive nucleoside analogue is administered when reactivation of HBV is observed.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 70 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
(1) Patient is planed to undergo 1st hematopoietic stem cell transplantation
(2) HBs antigen negative and anti-HBc antibody positive
(3) more than 20 year-old and less than 70 year-old
(4) Those patient who give written informed consent
Key exclusion criteria
(1) anti-HCV antibody negative
(2) anti-HIV antibody negative
(3) HBV DNA>=1.3 Log IU/mL
(4) anti-HBc antibody negative
(5) seroconversion of anti-HBc antibody negative to positive after infusion of blood product
(6) previous HBV reactivation
(7) previous history of treatment using nucleoside analogue, or plan to prescribe nucleoside analogue for prophylaxis
(8) anaphylaxis for previous vaccine
(9) conditioning regimen has been started for first HSCT
(10) complication of severe infection
(11) hemodialysis has been started or planed to be induced
(12) uncontrollable diabetics, hypertension or heart failure
(13) woman during pregnant or lactation
(14) patient who plan to move or plan to be followed by other institute during 2-year after HSCT
(15) patient who is not been considered to be eligible to the study by a doctor in charge by miscellaneous reasons
Target sample size
150
Research contact person
Name of lead principal investigator
| 1st name | Masashi |
| Middle name | |
| Last name | Mizokami |
Organization
National Center for Global Health and Medicine
Division name
Genome Medical Science Project
Zip code
272-8516
Address
1-7-1, Konodai, Ichikawa, Chiba
TEL
047-372-3501
mmizokami@hospk.ncgm.go.jp
Public contact
Name of contact person
| 1st name | Masahiro |
| Middle name | |
| Last name | Onozawa |
Organization
Hokkaido University Hospital
Division name
Department of Hematology
Zip code
060-8648
Address
Kita 14, Nishi 5, Kita-ku, Sapporo, Hokkaido
TEL
011-706-7214
Homepage URL
onozawa@med.hokudai.ac.jp
Sponsor or person
Institute
National Center for Global Health and Medicine
Genome Medical Science Project
Institute
Department
Personal name
Funding Source
Organization
Japan Agency for Medical Research and Development
Organization
Division
Category of Funding Organization
Japanese Governmental office
Nationality of Funding Organization
Other related organizations
Co-sponsor
The Japanese Data Center for Hematolopoietic Cell Transplantation
SRL
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Nagoya City University Hospital, Clinical Research Management Center
Address
Aza-kawasumi1, Mizuhocho, Mizuho-ku, Nagoya, Aichi
Tel
052-858-7215
clinical_research@med.nagoya-cu.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
北海道大学病院（北海道）
札幌北楡病院（北海道）
市立函館病院（北海道）
市立旭川病院（北海道）
岩手医科大学附属病院（岩手県）
東北大学病院（宮城県）
独立行政法人国立病院機構仙台医療センター（宮城県）
山形大学医学部附属病院（山形県）
自治医科大学附属病院（栃木県）
埼玉医科大学総合医療センター（埼玉県）
自治医科大学附属さいたま医療センター（埼玉県）
埼玉県立がんセンター(埼玉県)
成田赤十字病院（千葉県）
都立駒込病院（東京都）
慶應義塾大学病院（東京都）
日本医科大学付属病院（東京都）
神奈川県立がんセンター（神奈川県）
横浜市立大学附属市民総合医療センター（神奈川県）
新潟大学医歯学総合病院（新潟県）
金沢大学附属病院（金沢県）
長野赤十字病院（長野県）
岐阜大学医学部附属（岐阜県）
岐阜市民病院（岐阜県）
浜松医科大学附属病院（静岡県）
名古屋第一赤十字病院（愛知県）
名古屋大学医学部附属病院（愛知県）
国立病院機構名古屋医療センター（愛知県）
名古屋市立大学病院（愛知県）
安城更生病院（愛知県）
江南厚生病院（愛知県）
京都大学医学部附属病院（京都府）
大阪国際がんセンター（大阪府）
近畿大学医学部附属（大阪府）
兵庫県立がんセンター（兵庫県）
神戸市立医療センター中央市民病院（兵庫県）
神戸大学医学附属病院（兵庫県）
兵庫県立尼崎総合医療センター（兵庫県）
近畿大学医学部奈良病院（奈良県）
和歌山県立医科大学（和歌山県）
島根大学医学部附属病院（島根県）
倉敷中央病院（岡山県）
岡山大学病院（岡山県）
広島赤十字・原爆病院（広島県）
広島大学病院（広島県）
徳島大学病院（徳島県）
高知医療センター（高知県）
原三信病院（福岡県）
久留米大学病院（福岡県）
国立病院機構九州がんセンター（福岡県）
JCHO九州病院（福岡県）
佐賀大学医学部附属病院（佐賀県）
長崎大学病院（長崎県）
佐世保市総合医療センター（長崎県）
熊本大学病院（熊本県）
熊本医療センター（熊本県）
大分大学医学部附属病院（大分県）
宮崎大学医学部附属病院（宮崎県）
今村総合病院（鹿児島県）
鹿児島大学病院（鹿児島県）
Other administrative information
Date of disclosure of the study information
| 2018 | Year | 09 | Month | 24 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
109
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2018 | Year | 07 | Month | 14 | Day |
Date of IRB
| 2018 | Year | 09 | Month | 13 | Day |
Anticipated trial start date
| 2018 | Year | 09 | Month | 24 | Day |
Last follow-up date
| 2024 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2018 | Year | 09 | Month | 13 | Day |
Last modified on
| 2022 | Year | 09 | Month | 16 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037921
